Study #2020-0376
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Castrate Resistant Prostate Cancer
MD Anderson Study Status
Not Accepting
Treatment Agent
Etrumadenant, Zimberelimab, Enzalutamide, Docetaxel, Quemliclustat, SG
Description
This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of etrumadenant (AB928)-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Prostatic Neoplasms, Castration-Resistant, Androgen-Resistant Prostatic Neoplasms, Castration Resistant Prostatic Neoplasms, Prostatic Cancer, Castration-Resistant
Study phase:
Physician name:
Sumit Subudhi
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-855-757-2402
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.